CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia

Jesus Duque-Afonso, Chiou Hong Lin, Kyuho Han, David W. Morgens, Edwin E. Jeng, Ziming Weng, Johan Jeong, Stephen Hon Kit Wong, Li Zhu, Michael C. Wei, Hee Don Chae, Martin Schrappe, Gunnar Cario, Justus Duyster, Xiangshu Xiao, Kathleen M. Sakamoto, Michael C. Bassik, Michael L. Cleary

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Phþ acute lymphoblastic leukemia (ALL), but its efficacy is limited by resistance. Recent preclinical studies suggest that dasatinib may be a candidate therapy in additional ALL subtypes including pre-BCRþ ALL. Here we utilized shRNA library screening and global transcriptomic analysis to identify several novel genes and pathways that may enhance dasatinib efficacy or mitigate potential resistance in human pre-BCRþ ALL. Depletion of the transcriptional coactivator CBP increased dasatinib sensitivity by downregulating transcription of the pre-BCR signaling pathway previously associated with dasatinib sensitivity. Acquired resistance was due, in part, to upregulation of alternative pathways including WNT through a mechanism, suggesting transcriptional plasticity. Small molecules that disrupt CBP interactions with the CREB KID domain or b-catenin showed promising preclinical efficacy in combination with dasatinib. These findings highlight novel modulators of sensitivity to targeted therapies in human pre-BCRþ ALL, which can be reversed by small-molecule inhibitors. They also identify promising therapeutic approaches to ameliorate dasatinib sensitivity and prevent resistance in ALL. Significance: These findings reveal mechanisms that modulate sensitivity to dasatinib and suggest therapeutic strategies to improve the outcome of patients with acute lymphoblastic leukemia.

Original languageEnglish (US)
Pages (from-to)6497-6508
Number of pages12
JournalCancer Research
Volume78
Issue number22
DOIs
StatePublished - Nov 15 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Catenins
Dasatinib
Protein-Tyrosine Kinases
Small Interfering RNA
Up-Regulation
Down-Regulation
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Duque-Afonso, J., Lin, C. H., Han, K., Morgens, D. W., Jeng, E. E., Weng, Z., ... Cleary, M. L. (2018). CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia. Cancer Research, 78(22), 6497-6508. https://doi.org/10.1158/0008-5472.CAN-18-1703

CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia. / Duque-Afonso, Jesus; Lin, Chiou Hong; Han, Kyuho; Morgens, David W.; Jeng, Edwin E.; Weng, Ziming; Jeong, Johan; Wong, Stephen Hon Kit; Zhu, Li; Wei, Michael C.; Chae, Hee Don; Schrappe, Martin; Cario, Gunnar; Duyster, Justus; Xiao, Xiangshu; Sakamoto, Kathleen M.; Bassik, Michael C.; Cleary, Michael L.

In: Cancer Research, Vol. 78, No. 22, 15.11.2018, p. 6497-6508.

Research output: Contribution to journalArticle

Duque-Afonso, J, Lin, CH, Han, K, Morgens, DW, Jeng, EE, Weng, Z, Jeong, J, Wong, SHK, Zhu, L, Wei, MC, Chae, HD, Schrappe, M, Cario, G, Duyster, J, Xiao, X, Sakamoto, KM, Bassik, MC & Cleary, ML 2018, 'CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia', Cancer Research, vol. 78, no. 22, pp. 6497-6508. https://doi.org/10.1158/0008-5472.CAN-18-1703
Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z et al. CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia. Cancer Research. 2018 Nov 15;78(22):6497-6508. https://doi.org/10.1158/0008-5472.CAN-18-1703
Duque-Afonso, Jesus ; Lin, Chiou Hong ; Han, Kyuho ; Morgens, David W. ; Jeng, Edwin E. ; Weng, Ziming ; Jeong, Johan ; Wong, Stephen Hon Kit ; Zhu, Li ; Wei, Michael C. ; Chae, Hee Don ; Schrappe, Martin ; Cario, Gunnar ; Duyster, Justus ; Xiao, Xiangshu ; Sakamoto, Kathleen M. ; Bassik, Michael C. ; Cleary, Michael L. / CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia. In: Cancer Research. 2018 ; Vol. 78, No. 22. pp. 6497-6508.
@article{995ee7f651314684be68e0dc4e007874,
title = "CBP modulates sensitivity to dasatinib in pre-BCR{\th} acute lymphoblastic leukemia",
abstract = "Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Ph{\th} acute lymphoblastic leukemia (ALL), but its efficacy is limited by resistance. Recent preclinical studies suggest that dasatinib may be a candidate therapy in additional ALL subtypes including pre-BCR{\th} ALL. Here we utilized shRNA library screening and global transcriptomic analysis to identify several novel genes and pathways that may enhance dasatinib efficacy or mitigate potential resistance in human pre-BCR{\th} ALL. Depletion of the transcriptional coactivator CBP increased dasatinib sensitivity by downregulating transcription of the pre-BCR signaling pathway previously associated with dasatinib sensitivity. Acquired resistance was due, in part, to upregulation of alternative pathways including WNT through a mechanism, suggesting transcriptional plasticity. Small molecules that disrupt CBP interactions with the CREB KID domain or b-catenin showed promising preclinical efficacy in combination with dasatinib. These findings highlight novel modulators of sensitivity to targeted therapies in human pre-BCR{\th} ALL, which can be reversed by small-molecule inhibitors. They also identify promising therapeutic approaches to ameliorate dasatinib sensitivity and prevent resistance in ALL. Significance: These findings reveal mechanisms that modulate sensitivity to dasatinib and suggest therapeutic strategies to improve the outcome of patients with acute lymphoblastic leukemia.",
author = "Jesus Duque-Afonso and Lin, {Chiou Hong} and Kyuho Han and Morgens, {David W.} and Jeng, {Edwin E.} and Ziming Weng and Johan Jeong and Wong, {Stephen Hon Kit} and Li Zhu and Wei, {Michael C.} and Chae, {Hee Don} and Martin Schrappe and Gunnar Cario and Justus Duyster and Xiangshu Xiao and Sakamoto, {Kathleen M.} and Bassik, {Michael C.} and Cleary, {Michael L.}",
year = "2018",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-18-1703",
language = "English (US)",
volume = "78",
pages = "6497--6508",
journal = "Cancer Research",
issn = "0008-5472",
number = "22",

}

TY - JOUR

T1 - CBP modulates sensitivity to dasatinib in pre-BCRþ acute lymphoblastic leukemia

AU - Duque-Afonso, Jesus

AU - Lin, Chiou Hong

AU - Han, Kyuho

AU - Morgens, David W.

AU - Jeng, Edwin E.

AU - Weng, Ziming

AU - Jeong, Johan

AU - Wong, Stephen Hon Kit

AU - Zhu, Li

AU - Wei, Michael C.

AU - Chae, Hee Don

AU - Schrappe, Martin

AU - Cario, Gunnar

AU - Duyster, Justus

AU - Xiao, Xiangshu

AU - Sakamoto, Kathleen M.

AU - Bassik, Michael C.

AU - Cleary, Michael L.

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Phþ acute lymphoblastic leukemia (ALL), but its efficacy is limited by resistance. Recent preclinical studies suggest that dasatinib may be a candidate therapy in additional ALL subtypes including pre-BCRþ ALL. Here we utilized shRNA library screening and global transcriptomic analysis to identify several novel genes and pathways that may enhance dasatinib efficacy or mitigate potential resistance in human pre-BCRþ ALL. Depletion of the transcriptional coactivator CBP increased dasatinib sensitivity by downregulating transcription of the pre-BCR signaling pathway previously associated with dasatinib sensitivity. Acquired resistance was due, in part, to upregulation of alternative pathways including WNT through a mechanism, suggesting transcriptional plasticity. Small molecules that disrupt CBP interactions with the CREB KID domain or b-catenin showed promising preclinical efficacy in combination with dasatinib. These findings highlight novel modulators of sensitivity to targeted therapies in human pre-BCRþ ALL, which can be reversed by small-molecule inhibitors. They also identify promising therapeutic approaches to ameliorate dasatinib sensitivity and prevent resistance in ALL. Significance: These findings reveal mechanisms that modulate sensitivity to dasatinib and suggest therapeutic strategies to improve the outcome of patients with acute lymphoblastic leukemia.

AB - Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Phþ acute lymphoblastic leukemia (ALL), but its efficacy is limited by resistance. Recent preclinical studies suggest that dasatinib may be a candidate therapy in additional ALL subtypes including pre-BCRþ ALL. Here we utilized shRNA library screening and global transcriptomic analysis to identify several novel genes and pathways that may enhance dasatinib efficacy or mitigate potential resistance in human pre-BCRþ ALL. Depletion of the transcriptional coactivator CBP increased dasatinib sensitivity by downregulating transcription of the pre-BCR signaling pathway previously associated with dasatinib sensitivity. Acquired resistance was due, in part, to upregulation of alternative pathways including WNT through a mechanism, suggesting transcriptional plasticity. Small molecules that disrupt CBP interactions with the CREB KID domain or b-catenin showed promising preclinical efficacy in combination with dasatinib. These findings highlight novel modulators of sensitivity to targeted therapies in human pre-BCRþ ALL, which can be reversed by small-molecule inhibitors. They also identify promising therapeutic approaches to ameliorate dasatinib sensitivity and prevent resistance in ALL. Significance: These findings reveal mechanisms that modulate sensitivity to dasatinib and suggest therapeutic strategies to improve the outcome of patients with acute lymphoblastic leukemia.

UR - http://www.scopus.com/inward/record.url?scp=85056577080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056577080&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-1703

DO - 10.1158/0008-5472.CAN-18-1703

M3 - Article

VL - 78

SP - 6497

EP - 6508

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -